Stratagene CEO Joe Sorge circled the date — March 28, 2005 — in the company's fourth-quarter conference call last week.

"This will mark the beginning of an opportunity for us to move into the molecular diagnostics market," Sorge said.

Why March 28? On that date, Roche's core PCR patents will expire, and Sorge, like others in the molecular biology tools market, is preparing to be freed from the patent barriers that kept his company from using the technology more broadly.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.